Navegando por Autor "Cardoso, Francisco Eduardo Costa"

Agora exibindo 1 - 4 de 4

Parkinsonian signs and symptoms in adults with a history of Sydenham’s chorea.
(2012) Barreto, Leonardo Brandão; Maciel, Ricardo Oliveira Horta; Maia, Débora Palma; Teixeira, Antônio Lúcio; Cardoso, Francisco Eduardo Costa
Background: Sydenham’s chorea is associated with dysfunction of fronto-striatal circuits induced by crossreactive antibodies to group A b-hemolytic streptococcus. High susceptibility of extrapyramidal effects of neuroleptics in patients with Sydenham’s chorea suggests underlying nigro-striatal dysfunction. Objective: To study the presence of parkinsonism in patients with a history of Sydenham’s Chorea. Methods: We used the UFMG Sydenham’s Chorea Rating Scale (USCRS) and the Unified Parkinson’s Disease Rating Scale (UPDRS) part III, respectively, to determine the presence of chorea and parkinsonian symptoms and signs in 25 adults with a history of previous Sydenham’s Chorea currently without chorea or use of anti-choreic drugs. Results: Bradykinesia was found in 64% of subjects. There was a statistically significant correlation between bradykinesia and hemichorea (_0.412; p ¼ 0.036) and bradykinesia and generalized chorea (0.412; p ¼ 0.036). There was no correlation between bradykinesia and use of anti-choreic drugs. Conclusions: Bradykinesia is common in patients with Sydenham’s Chorea in remission. This finding suggests an immune-mediated dysfunction of the nigro-striatal system.
Parkinsonian signs and symptoms in adults with a history of Sydenham’s chorea.
(2012) Barreto, Leonardo Brandão; Maciel, Ricardo Oliveira Horta; Maia, Débora P.; Teixeira, Antônio Lúcio; Cardoso, Francisco Eduardo Costa
Background: Sydenham’s chorea is associated with dysfunction of fronto-striatal circuits induced by crossreactive antibodies to group A b-hemolytic streptococcus. High susceptibility of extrapyramidal effects of neuroleptics in patients with Sydenham’s chorea suggests underlying nigro-striatal dysfunction. Objective: To study the presence of parkinsonism in patients with a history of Sydenham’s Chorea. Methods: We used the UFMG Sydenham’s Chorea Rating Scale (USCRS) and the Unified Parkinson’s Disease Rating Scale (UPDRS) part III, respectively, to determine the presence of chorea and parkinsonian symptoms and signs in 25 adults with a history of previous Sydenham’s Chorea currently without chorea or use of anti-choreic drugs. Results: Bradykinesia was found in 64% of subjects. There was a statistically significant correlation between bradykinesia and hemichorea ( 0.412; p ¼ 0.036) and bradykinesia and generalized chorea (0.412; p ¼ 0.036). There was no correlation between bradykinesia and use of anti-choreic drugs. Conclusions: Bradykinesia is common in patients with Sydenham’s Chorea in remission. This finding suggests an immune-mediated dysfunction of the nigro-striatal system.
Reversible parkinsonism after chronic cyclosporin treatment in renal transplantation.
(2009) Viana, Bernardo de Mattos; Moura, André de Souza; Moreira, Janaina Matos; Cano Prais, Hugo Alejandro; Cardoso, Francisco Eduardo Costa
Ziprasidone-related oculogyric crisis in an adult.
(2009) Viana, Bernardo de Mattos; Cano Prais, Hugo Alejandro; Camargos, Sarah Teixeira; Cardoso, Francisco Eduardo Costa
Introduction: Drug-induced dyskinesias arecommonside-effects of first-generation antipsychotics (FGAs) but are not usually related to second-generation antipsychotics (SGAs). Oculogyric crisis (OGC) is a disabling acute dystonia that affects extra-ocular muscles usually resulting in an upward deviation of the eyes, which lasts from minutes to hours. Case report:Wedescribe an adult patient, previously exposed to an FGA,whodevelopedOGCon 80 mg/day of ziprasidone. The movement disorder significantly improved after use of 1 mg/day of clonazepam without the need to switch to another SGA. Discussion: The clinical features of the movement disorder of our patient meet the criteria for OGC. It is, sometimes, difficult to directly correlate a drug-induced dyskinesia to a SGA due to previous exposures to FGAs. The onset of OGC after exposure to ziprasidone without simultaneous use of other antipsychotic suggests a casual relationship between the former and the movement disorder. It is possible that previous use of an FGA was a risk factor for the development of OGC. Conclusion: To the best of our knowledge, this is the first report of ziprasidone-related OGC in an adult patient. Physicians must be aware of its occurrence in order to improve care of patients treated with these agents.